May 09, 2024 4:05pm EDT Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
May 07, 2024 8:00am EDT Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
May 02, 2024 7:00am EDT Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
Apr 30, 2024 8:00am EDT In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Mar 27, 2024 4:05pm EDT Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Mar 25, 2024 8:00am EDT Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Mar 22, 2024 9:15am EDT Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Mar 22, 2024 6:30am EDT Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
Feb 26, 2024 8:00am EST Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
